- Cardiome Pharma (CRME -1.1%) consummates a deal with a syndicate of underwriters under which they will purchase, on a bought deal basis, 1.875M shares of common stock at $8 per share. Gross proceeds will be $15M. Underwriters over-allotment is an additional 281,250 shares. Closing date is August 13.
- Bought deal financing means that the underwriters have agreed to purchase all the shares.